The MammoSite ML (multi-lumen) device offers more women the option of completing their radiation treatment in just five days

BEDFORD, Mass., September 1, 2009 - Hologic, Inc. (Hologic or the Company) (NASDAQ:
HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical
imaging systems and surgical products dedicated to serving the healthcare needs of women,
today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K
application for the MammoSite® ML radiation therapy system. With its multi-lumen design, this
new device gives radiation oncologists the ability to shape the radiation dose for typical cases
and treat patients who are otherwise not appropriate candidates for traditional brachytherapy.

Hologic's MammoSite therapy system, first cleared by the FDA in 2002 as a single-lumen
device, is the most widely used form of accelerated partial breast irradiation (APBI) in the
United States. It has been used to treat more than 50,000 breast cancer patients in the U.S.

By employing the MammoSite system, the physician can deliver targeted radiation therapy
directly to the area where cancer is most likely to recur,i allowing a full course of radiation to be
delivered in just five days. Additionally, targeted therapy of the breast limits radiation exposure
to normal, healthy tissue. This targeting helps minimize side effects such as skin discoloration
and scarring, burning, fatigue, and damage to surrounding organs.

In 2008, approximately 240,000 cases of breast cancer were confirmed in the U.S. Fortunately,
today more than half of breast cancers are diagnosed when the disease is still in its localized
stage. ii Early detection allows breast cancer patients to choose breast conservation therapy,
which preserves the breast by relying on tumor excision via lumpectomy, followed by radiation
therapy, to reduce the likelihood of recurrence. According to the National Institutes of Health,
breast-conserving surgery plus radiation therapy is preferable to total mastectomy because it
provides survival equivalence while preserving the breast.iii

The MammoSite systems are comprised of an inflatable balloon catheter in which a radioactive
source is introduced for therapy delivery. The inflatable balloon is inserted into the surgical
cavity remaining after removal of the tumor. This local placement of the balloon provides for
therapeutic delivery of a five-day course of radiation to the tissue most likely to contain residual
cancerous cells following surgery, while reducing radiation exposure to adjacent healthy tissue.
Using the MammoSite multi-lumen catheter, the radiation oncologist has the ability to shift the
radiation dose to the areas that need it most and shift the dose away from areas that do not
require it.

"An increasing number of surgeons, radiation oncologists, and patients are choosing the
accelerated treatment available with MammoSite," said David Harding, senior vice president of
Hologic's interventional breast solutions business. "Now, with MammoSite ML, five-day
targeted radiation therapy is also available to women with early-stage tumors close to the skin or
chest wall who may not have been good candidates for traditional balloon brachytherapy. This is
another significant milestone for Hologic and our interventional breast solutions business. With
FDA clearance of the MammoSite ML radiation therapy system, we are now able to provide
surgeons and radiation oncologists with a device designed to both maximize patient comfort and
enable greater physician flexibility in delivering targeted radiation therapy directly to the areas
where breast cancers are most likely to recur."

The Company expects to commercially launch MammoSite ML during the first quarter of fiscal
year 2010 (quarter ending December 26, 2009). Please see www.mammosite.com for additional
information on the MammoSite targeted radiation therapy system.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products,
medical imaging systems and surgical products dedicated to serving the healthcare needs of
women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical,
and skeletal health. Hologic provides a comprehensive suite of technologies with products for
mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical
cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment,
preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic
products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and
uncertainties, including statements about the use of the MammoSite and MammoSite ML
targeted radiation therapy systems. There can be no assurance the system will achieve the
benefits described herein and that such benefits will be replicated in any particular manner with
respect to an individual patient as the actual effect of the use of the MammoSite targeted
radiation therapy systems can only be determined on a case-by-case basis depending on the
particular circumstances and patient in question. Hologic expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to the data or statements presented
herein to reflect any change in the Company's expectations or any change in events, conditions
or circumstances on which any such data or statements are based. Certain factors that could
adversely affect the Company's business and prospects are described in Hologic filings with the
Securities and Exchange Commission.